“Can a nurse practitioner prescribe peptides?” is the wrong question, and asking it the wrong way is how practices end up in trouble.
There is no peptide-specific prescribing law. No state board maintains a list of peptides an NP may or may not prescribe. What exists is your ordinary prescriptive authority, which varies enormously by state and by profession — layered on top of a federal framework that governs whether the substance may lawfully exist in a compounded form at all.
Get those two layers straight and the answer becomes clear for your own situation.
Layer one: your prescriptive authority
For nurse practitioners, states fall broadly into three arrangements. In full practice authority states, NPs evaluate, diagnose and prescribe under the exclusive licensure authority of the board of nursing. In reduced practice states, at least one element of practice requires a collaborative agreement with a physician. In restricted practice states, career-long supervision or delegation by a physician is required.
Physician assistants operate under a different model again, generally practising under physician supervision or collaboration with the specifics — chart review requirements, ratios, delegation agreements — set state by state.
None of this is peptide-specific. If you may prescribe Schedule-appropriate medications within your scope in your state, the question of whether a given peptide is prescribable turns on layer two, not layer one.
Because these arrangements change through legislation with some regularity, the only reliable source is your own state board and your collaborative or supervisory agreement as written. We are deliberately not publishing a state-by-state table here: a table that is wrong in one state is worse than no table at all, and prescribing decisions should not rest on a blog post’s reading of your practice act.
Layer two: whether the substance is prescribable at all
This is where most peptides actually fail, and it applies equally to physicians.
An FDA-approved peptide drug — semaglutide, tirzepatide, sermorelin, teriparatide — is prescribed like any other prescription medication, within your scope.
An unapproved peptide reaches a patient only through compounding, and a 503A pharmacy may only compound from a substance that is a component of an approved drug, appears on the FDA’s 503A bulk drug substances list, or has an applicable USP or NF monograph. Most peptides discussed in wellness practice satisfy none of those conditions. In that situation it does not matter what your prescriptive authority is — there is no lawful preparation to prescribe.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Functional & Regenerative Medicine courses — live patients, expert faculty, and ongoing mentorship.
This is the distinction that catches practices out. A clinician with full prescriptive authority still cannot lawfully obtain a compounded preparation of an ineligible substance, and a pharmacy willing to make it anyway is not evidence that they can.
Layer three: the things that actually get people sanctioned
In practice, board actions in this space rarely turn on the molecule. They turn on the file:
- Documented medical necessity. Why this patient, this indication, this therapy, at this time. A protocol applied uniformly to everyone who walks in reads as a product, not a clinical decision.
- Informed consent covering non-FDA-approved use. Patients must understand that a compounded preparation is not an approved product and what that means for evidence and oversight.
- A real evaluation. History, examination, appropriate baseline labs, and a monitoring plan — not an intake form and a shipment.
- Supervision and delegation that matches your agreement. If your state requires collaboration, the collaboration has to exist in practice, not only on paper.
- Advertising that matches your scope. Claims made publicly are discoverable, and they are read against what you are actually permitted to do.
Telehealth makes all of this harder
Prescribing across state lines means meeting the licensure requirements of the state where the patient is located, not where you are. Add remote-prescribing rules, standard-of-care expectations for a virtual evaluation, and supervision arrangements that may not travel with you, and a multi-state peptide practice becomes a genuinely complex legal structure rather than a website with a booking link.
Frequently asked questions
Can a nurse practitioner prescribe peptides?
Within their state’s prescriptive authority, an NP may prescribe an approved peptide drug like any other medication. For unapproved peptides, the limiting factor is usually federal compounding eligibility rather than the NP’s scope.
Can a physician assistant prescribe peptides?
Same analysis. PA prescriptive authority is set by state law and the supervisory or collaborative agreement, and the compounding question applies identically.
Is there a peptide-specific licence or certification required?
No state requires a peptide-specific credential to prescribe. Certification demonstrates training and competence; it does not expand scope of practice.
Does a certification let me prescribe something I otherwise could not?
No. No certification alters your licence, your scope, or federal compounding law.
Can an RN administer peptide injections?
Administration under a valid order is generally within RN scope, subject to state nurse practice acts and facility policy. Selecting and prescribing the therapy is a separate authority.
Get the framework, not a rumour
Module 12 of the Empire Peptide Therapy Certification is taught with a healthcare law firm and covers scope of practice, delegation and medical direction, documentation of medical necessity, and telehealth and multi-state structure. Module 2 covers the 503A and 503B framework that decides layer two.
Related: 503A vs 503B compounding for prescribers.
